ClinicalTrials.gg
CompletedNCT05237804TREATUpdated Nov 6, 2026

Evaluation of an Intervention to Reduce the Time to Treatment for TAVI Patients

An interventional study of Patient component and Organisational component in Aortic Valve Stenosis, sponsored by University Hospital, Rouen. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Other

How we know

Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
828
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Aortic Valve Stenosis with a site in France — 22 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · France.

Enrollment
15th of 69
828 · median 186
Started
2022
with 3 others
No phase
58 of 131
8 open now
Registered
108th of 131
by date
Lead sponsor
7 of 131
University Hospital, Rouen

Among the 131 studies in Aortic Valve Stenosis with a site in France, this one is the 15th largest by enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2022, is one of 58 with no phase, and was the 108th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

22 of the 131 studies in Aortic Valve Stenosis with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Aortic Valve Stenosis with a site in France, or all of them as a file.
02

Study summary

Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).

Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.

In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • Aortic Stenosis
  • Treatment time
  • Medico-economy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age;
  • Aortic stenosis
  • Indication of TAVI
  • Patient affiliated or benefiting from a health insurance scheme
  • Patient having read and understood the information letter and having signed the consent form

Exclusion criteria

Exclusion Criteria:

  • TAVI indication not retained
  • Patient who are not fluent in French and have no one around them to translate,
  • Patient who do not have access to the Internet (at home or in their immediate environment)
  • Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective (as defined by the WHO) or woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
  • Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
  • History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
828 participants (actual)

Study arms

  • No intervention
    Control group

    The randomized centres in this group will not change their practices.

  • Experimental
    Patient component

    The randomized centres in this group will be required to present patients with: * A short introductory video, viewed on a tablet during hospitalization for coronary angiography, * A paper booklet, * A website.

    Other: Patient component

  • Experimental
    Organisational component

    The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.

    Other: Organisational component

  • Experimental
    Patient and organisational components

    The randomized centres in this group will have to implement the two components.

    Other: Patient component · Other: Organisational component

Interventions

  • OtherPatient component

    Video, booklet, website

  • OtherOrganisational component

    Coronarography, CT-scan, anesthesia...

06

What researchers measure

Primary outcomes

  1. To evaluate the effectiveness of an intervention combining a patient component and an organisational component

    Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months

    Time frame: Month 6

Secondary outcomes

  1. Time to care, in days

    The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure

    Time frame: Month 6

  2. Mortality rate

    The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure

    Time frame: Months 3 and 6

  3. Patients' health-related quality of life

    Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L).

    Time frame: Baseline, Months 3 and 6

  4. Patient knowledge of the disease and the TAVI procedure

    Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score).

    Time frame: Baseline, Month 3

  5. Medication compliance

    Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance).

    Time frame: Month 6

  6. Patient satisfaction

    Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale

    Time frame: Month 6

  7. Number of visits to the patient section of the website

    The number of visits to the website will be assessed through Googleanalytics®

    Time frame: Month 6

  8. Number of visits to the professional section of the website

    The number of visits to the website will be assessed through Googleanalytics®

    Time frame: Month 6

  9. Acceptability of the intervention for participating centers

    The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment.

    Time frame: Month 6

  10. Intervention components' dose and fidelity

    Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol.

    Time frame: Month 6

  11. Reached populations

    Percentage of target individuals who benefit from activities of each component of the intervention

    Time frame: Month 6

  12. Intervention components' adaptation

    Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided.

    Time frame: Month 6

  13. Incremental cost-effectiveness ratio

    The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire

    Time frame: Month 6

07

Study locations

2 sites
  • Brest University Hospital
    Brest, France
  • CHU de Rouen
    Rouen, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Oct 2025, 35 months.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 35 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2024 → Oct 2025, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Feb 14, 2022
StartActual
Oct 26, 2022
Primary completionActual
Oct 23, 2025was Oct 2024
CompletionActual
Oct 23, 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 25, 2024→Oct 23, 2025
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Oct 25, 2024→Oct 23, 2025

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05237804
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Oct 26, 2022
Primary completion
Oct 23, 2025
Completion
Oct 23, 2025
Last update
Nov 6, 2026

Study contacts

Helene Eltchaninoff, Pr
principal investigator · University Hospital, Rouen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion